Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price, Quote, News and Overview

TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD

11.98  +0.31 (+2.66%)

FRX.CA Quote, Performance and Key Statistics

FENNEC PHARMACEUTICALS INC

TSX:FRX (7/17/2025, 7:00:00 PM)

11.98

+0.31 (+2.66%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High12.99
52 Week Low5.65
Market Cap330.89M
Shares27.62M
Float22.83M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE10.33
Earnings (Next)08-07 2025-08-07/bmo
IPO06-05 2001-06-05


FRX.CA short term performance overview.The bars show the price performance of FRX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

FRX.CA long term performance overview.The bars show the price performance of FRX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of FRX.CA is 11.98 CAD. In the past month the price increased by 5.64%. In the past year, price increased by 42.28%.

FENNEC PHARMACEUTICALS INC / FRX Daily stock chart

FRX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 267.18M
EDT.CA SPECTRAL MEDICAL INC N/A 231.27M
TH.CA THERATECHNOLOGIES INC N/A 198.63M
ONC.CA ONCOLYTICS BIOTECH INC N/A 158.10M
WLLW.CA WILLOW BIOSCIENCES INC N/A 144.77M
HBP.CA HELIX BIOPHARMA CORP N/A 74.16M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 73.37M
COV.CA COVALON TECHNOLOGIES LTD 19.92 71.02M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 58.20M
BLU.CA BLUENERGIES LTD N/A 55.79M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 41.96M
MBX.CA MICROBIX BIOSYSTEMS INC 29.5 41.47M

About FRX.CA

Company Profile

FRX logo image Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Company Info

FENNEC PHARMACEUTICALS INC

PO Box 13628, 68 Tw Alexander Dr

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US

CEO: Rostislav Raykov

Employees: 36

FRX Company Website

FRX Investor Relations

Phone: 19196364530

FENNEC PHARMACEUTICALS INC / FRX.CA FAQ

What is the stock price of FENNEC PHARMACEUTICALS INC today?

The current stock price of FRX.CA is 11.98 CAD. The price increased by 2.66% in the last trading session.


What is the ticker symbol for FENNEC PHARMACEUTICALS INC stock?

The exchange symbol of FENNEC PHARMACEUTICALS INC is FRX and it is listed on the Toronto Stock Exchange exchange.


On which exchange is FRX.CA stock listed?

FRX.CA stock is listed on the Toronto Stock Exchange exchange.


What is the price forecast or stock price prediction for FENNEC PHARMACEUTICALS INC stock?

11 analysts have analysed FRX.CA and the average price target is 17.71 CAD. This implies a price increase of 47.8% is expected in the next year compared to the current price of 11.98. Check the FENNEC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FENNEC PHARMACEUTICALS INC worth?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 330.89M CAD. This makes FRX.CA a Small Cap stock.


How many employees does FENNEC PHARMACEUTICALS INC have?

FENNEC PHARMACEUTICALS INC (FRX.CA) currently has 36 employees.


What are the support and resistance levels for FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a support level at 10.9 and a resistance level at 12.17. Check the full technical report for a detailed analysis of FRX.CA support and resistance levels.


Is FENNEC PHARMACEUTICALS INC (FRX.CA) expected to grow?

The Revenue of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to decline by -16.58% in the next year. Check the estimates tab for more information on the FRX.CA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FENNEC PHARMACEUTICALS INC (FRX.CA) stock pay dividends?

FRX.CA does not pay a dividend.


When does FENNEC PHARMACEUTICALS INC (FRX.CA) report earnings?

FENNEC PHARMACEUTICALS INC (FRX.CA) will report earnings on 2025-08-07, before the market open.


What is the Price/Earnings (PE) ratio of FENNEC PHARMACEUTICALS INC (FRX.CA)?

FENNEC PHARMACEUTICALS INC (FRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).


FRX.CA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA is one of the better performing stocks in the market, outperforming 87.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

FRX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA. While FRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FRX.CA Financial Highlights

Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -666.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.11%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-108.51%
Sales Q2Q%-65.52%
EPS 1Y (TTM)-666.67%
Revenue 1Y (TTM)-31.25%

FRX.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to FRX.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 308694732858483400% and a revenue growth -16.58% for FRX.CA


Ownership
Inst Owners56.62%
Ins Owners1.91%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.45
Price Target17.71 (47.83%)
EPS Next Y308694732858483400%
Revenue Next Year-16.58%